RadNet (RDNT) shares surged 5.08% intraday on Wednesday, driven by Barclays' bullish stance on the medical imaging company.
Barclays analyst Andrew Mok CFA maintained a Buy rating on RadNet and set a price target of $74.00. This positive outlook from the analyst appears to be fueling the stock's rally.
RadNet has been viewed favorably by analysts due to its strong growth prospects and leadership position in the outpatient imaging services market. The company is expected to benefit from increasing demand for diagnostic imaging procedures as the population ages.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。